Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Thursday, Zacks.com reports. The firm presently has a $6.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 11.02% from the […]
- Updated Phase 3 SIERRA data to be presented in an oral presentation by Boglarka Gyurkocza, M.D., SIERRA trial investigator from Memorial Sloan Kettering.
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for.
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.
/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for.